Bispecifics in Multiple Myeloma: Adverse Event Management

Expert perspectives on adverse event management in patients on bispecific therapy for multiply relapsed multiple myeloma.

Related Keywords

,Evolving Treatment Paradigm ,Multiple Myeloma ,Recent Updates ,Adverse Event Management ,Myeloma Cancer ,Relapsed Refractory Multiple Myeloma ,Multiply Relapsed ,Later Line Treatment ,Later Line Therapy ,Adverse Events ,Drug Adverse Event ,Crs ,Cytokine Release Syndrome ,Pelicans ,Immune Effector Cell Associated Neurotoxicity Syndrome ,Prophylaxis ,Prophylactic Treatment ,Tocilizumab ,Asco 2023 ,Asco Annual Meeting ,